Breaking News, Promotions & Moves

Alcanza Names Bob Kinard President and COO

Kinard brings operational, financial leadership, business development and strategic planning experience.

Alcanza Clinical Research, a mission-focused investigator site network, appointed 30-year industry veteran Bob Kinard President and Chief Operating Officer. Kinard’s experience includes operational and financial leadership, business development and strategic planning for a variety of health systems spanning physician practices, ambulatory and outpatient centers, as well as specialty care. At Alcanza, Kinard will oversee clinical operations, patient engagement and quality and compliance functions. In addition, he will lead integration activities across the company’s expanding site network.

Most recently, Kinard served as COO for GoHealth Urgent Care, where he led the company’s growth from 75 to 250 locations across 14 states. Prior to that, he was executive vice president of operations for Schumacher Clinical Partners, where he focused on clinical practice management spanning emergency, hospital, and critical care medicine.

“Clinical research is at an inflection point,” said Carlos Orantes, Alcanza CEO. “To stay ahead of rapidly changing research practices and regulatory expectations, investigator sites need operational excellence at scale, therapeutic specialty breadth and sophisticated patient engagement solutions to broaden participation. Bob’s deep understanding of clinical care operations and his track record of leading healthcare organizations with complex service lines through transformational growth will accelerate our network expansion and help us deliver on the promise of inclusive research.”

Kinard said, “I look forward to being a part of Alcanza as we help biopharmaceutical sponsors conduct clinical research that delivers the next generation of medicine. I am impressed with the commitment of the leadership team and the investment from Martis Capital to drive sustainable growth in Alcanza’s differentiated approach to clinical research. It’s an exciting time for clinical development, as we continue to solve for persistent challenges in participant diversity and access to research across underrepresented communities.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters